Now showing items 1-3 of 3
Optimal designs for dose-finding in contingent response models
(University of Missouri--Columbia, 2004-12)
We study D- and c-optimal designs for dose-finding with opposing failure functions. In particular, we study the contingent response models of Li, Durham and Flournoy (1995). In the contingent response model, there are two ...
Differential expression of BRCC2, a novel BH3-like domain-containing apoptotic molecule, in ductal versus lobular breast carcinoma
(American Association for Cancer Research, 2007)
Background: BRCC2 (breast cancer cell 2) gene was discovered as an approximately 1.2 kb transcript in MDA-MB 231 human breast cancer cells (GenBank accession numbers AF220061 and AF303179). BRCC2 is a 12 kDa cytosolic ...
Optimal designs for contingent response models
We study D- and c-optimal designs for the contingent response models of (1995). In the contingent response model there are two types of failure. We call one failure type toxicity and the other disease failure. No toxicity ...